Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Payables (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Payables over the past 10 years, most recently at $3.5 million for Q4 2023.

  • For Q4 2023, Payables rose 37.7% year-over-year to $3.5 million; the TTM value through Dec 2023 reached $3.5 million, up 37.7%, while the annual FY2023 figure was $3.5 million, 37.7% up from the prior year.
  • Payables for Q4 2023 was $3.5 million at Corbus Pharmaceuticals Holdings, down from $4.7 million in the prior quarter.
  • Over five years, Payables peaked at $12.8 million in Q2 2020 and troughed at $1.4 million in Q3 2022.
  • A 5-year average of $5.4 million and a median of $3.8 million in 2021 define the central range for Payables.
  • Biggest five-year swings in Payables: crashed 84.53% in 2021 and later skyrocketed 243.0% in 2023.
  • Year by year, Payables stood at $11.8 million in 2019, then tumbled by 31.68% to $8.1 million in 2020, then crashed by 68.48% to $2.6 million in 2021, then decreased by 0.9% to $2.5 million in 2022, then soared by 37.7% to $3.5 million in 2023.
  • Business Quant data shows Payables for CRBP at $3.5 million in Q4 2023, $4.7 million in Q3 2023, and $1.6 million in Q2 2023.